The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1632
ISSUE1632
September 6, 2021
Rilonacept (Arcalyst) for Recurrent Pericarditis
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Rilonacept (Arcalyst) for Recurrent Pericarditis
September 6, 2021 (Issue: 1632)
Rilonacept (Arcalyst – Kiniksa), an interleukin-1 (IL-1)
antagonist that has been available for years for
treatment of cryopyrin-associated periodic syndromes,
has now been approved by the FDA for treatment
of recurrent pericarditis and...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.